Harwood Feffer LLP Announces Investigation of Dimension Therapeutics, Inc.
Oct 5, 2017
NEW YORK, Oct. 5, 2017 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Dimension Therapeutics, Inc. ("Dimension" or the "Company") (NASDAQ: DMTX) concerning the proposed sale of the Company to Ultragenyx Pharmaceutical, Inc. ("Ultragenyx").
Under the terms of the offer, Ultragenyx would acquire Dimension in a transaction valued at approximately $151 million. Pursuant to the deal, Dimension stockholders will receive $6.00 in cash per share.
Our investigation concerns whether the Dimension board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders.
If you own Dimension shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Daniella Quitt, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP